차이
문서의 선택한 두 판 사이의 차이를 보여줍니다.
양쪽 이전 판이전 판다음 판 | 이전 판 | ||
med:antenatal_corticosteroid [2025/05/26 05:30] – [Old] V_L | med:antenatal_corticosteroid [2025/05/26 05:55] (현재) – [양막파수] V_L | ||
---|---|---|---|
줄 20: | 줄 20: | ||
- | =====Old===== | ||
+ | =====양막파수==== | ||
- | < | + | ^ **기관** |
- | all women between | + | | **ACOG (미국산부인과학회, |
+ | | **NICE (영국국립보건임상연구소)** | ||
+ | | **WHO (세계보건기구, | ||
- | * betamethasone 12 mg IM 24시간 간격 | ||
- | * dexamethasone 6 mg IM 4회 12 시간 간격 | ||
- | + | * [[prom|PROM(조기양막파열)]] 시에는 산모 감염(융모양막염 등) 감시가 중요합니다. | |
- | WHO recommends that a single repeat course of steroids may be considered if preterm birth does not occur within 7 days after the initial course and subsequent assessment demonstrates that there is a high risk of preterm birth in the next 7 days</ | + | * 스테로이드는 1회만 사용하며, 반복 투여는 권장되지 않습니다. |
- | + | ||
- | [[https:// | + | |
- | + | ||
- | =====기타===== | + | |
- | + | ||
- | ====양막파수==== | + | |
- | + | ||
- | 32주 까지만... | + | |
- | + | ||
- | • ACS therapy is indicated in women with PROM from | + | |
- | 24 to 32 weeks’ gestation not presenting clinical signs | + | |
- | of chorioamnionitis. | + | |
- | + | ||
- | This scenario includes considerable risk of infection for | + | |
- | the mother and the fetus. The evidence justifying the use | + | |
- | of ACS in PROM is based on two major meta-analyses: | + | |
- | In the 2006 Cochrane Review w37x ‘‘ACS are shown to | + | |
- | be beneficial in the subgroup of infants whose mothers | + | |
- | have PROM. Neonatal death, RDS, IVH, NEC, and duration of respiratory support are all reduced, without an | + | |
- | increase in either maternal or neonatal infection’’. Similar | + | |
- | results were obtained from Harding et al.’s meta-analysis | + | |
- | in 2001 w17x. | + | |
- | + | ||
- | Beyond 32 weeks of gestation, the risk of | + | |
- | chorioamnionitis is higher than the risks derived from | + | |
- | prematurity w15, 24x. | + |